Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 15/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | RAF1 | P04049 | 2/20 | 0.51 |
| ▸ | BRAF | P15056 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1834743 | 1.00 | MDM2 (0.76) | MDM2CYP2D6CYP3A4RAF1BRAF | |
| SCHEMBL4907041 | 0.89 | MDM2 (0.80) | MDM2CYP2D6CYP3A4RAF1BRAF | |
| SCHEMBL4907039 | 0.89 | MDM2 (0.80) | MDM2CYP2D6CYP3A4RAF1BRAF | |
| SCHEMBL1826342 | 0.86 | MDM2 (1.00) | MDM2CYP2D6CYP3A4 | |
| SCHEMBL4907072 | 0.86 | MDM2 (1.00) | MDM2CYP2D6CYP3A4 | |
| SCHEMBL18568818 | 0.84 | MDM2 (0.54) | MDM2CYP2D6CYP3A4L3MBTL1 | |
| SCHEMBL1822327 | 0.83 | MDM2 (0.56) | MDM2CYP2D6CYP3A4 | |
| SCHEMBL1823371 | 0.82 | MDM2 (0.88) | MDM2CYP2D6CYP3A4 | |
| SCHEMBL11000820 | 0.81 | MDM2 (0.61) | MDM2CYP2D6CYP3A4 | |
| SCHEMBL6962121 | 0.79 | MDM2 (0.58) | MDM2CYP2D6CYP3A4RAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786773-B1 | ISOINDOLIN-1-ONE DERIVATIVES | CANCER RES TECH LTD (GB) | 2017-03-01 | — | — | EP | disclosed |
| US-8258175-B2 | Prodrug; novel series of compounds which inhibit the MDM2-p53 interaction and have in vitro activity exerting an anti-tumour effect; cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-09-04 | — | — | US | disclosed |
| US-20080261917-A1 | Isoindolin-1-One Derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261917-A1 | Isoindolin-1-One Derivatives | HCN3, NHERF1, SIGMAR1 | MDM2 1568/4885CYP2D6 82/4885CYP3A4 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.